vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Fabrinet (FN). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $1.1B, roughly 1.0× Fabrinet). Fabrinet runs the higher net margin — 9.9% vs -24.1%, a 34.1% gap on every dollar of revenue. On growth, Fabrinet posted the faster year-over-year revenue change (35.9% vs 12.2%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $-5.3M). Over the past eight quarters, Fabrinet's revenue compounded faster (24.4% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
FabrinetFNEarnings & Financial Report
Below is a list of companies having stocks that are included in the S&P MidCap 400 stock market index. The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 400 mid-cap, mostly American, companies. Although called the S&P 400, the index sometimes contains more than 400 stocks when it includes two or more share classes of stock from one of its component companies.
ELAN vs FN — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.1B |
| Net Profit | $-276.0M | $112.6M |
| Gross Margin | 51.5% | 12.2% |
| Operating Margin | -22.6% | 10.1% |
| Net Margin | -24.1% | 9.9% |
| Revenue YoY | 12.2% | 35.9% |
| Net Profit YoY | -3350.0% | 30.0% |
| EPS (diluted) | $-0.55 | $3.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $978.1M | ||
| Q2 25 | $1.2B | $909.7M | ||
| Q1 25 | $1.2B | $871.8M | ||
| Q4 24 | $1.0B | $833.6M | ||
| Q3 24 | $1.0B | $804.2M | ||
| Q2 24 | $1.2B | $753.3M | ||
| Q1 24 | $1.2B | $731.5M |
| Q4 25 | $-276.0M | $112.6M | ||
| Q3 25 | $-34.0M | $95.9M | ||
| Q2 25 | $11.0M | $87.2M | ||
| Q1 25 | $67.0M | $81.3M | ||
| Q4 24 | $-8.0M | $86.6M | ||
| Q3 24 | $364.0M | $77.4M | ||
| Q2 24 | $-50.0M | $81.1M | ||
| Q1 24 | $32.0M | $80.9M |
| Q4 25 | 51.5% | 12.2% | ||
| Q3 25 | 53.4% | 11.9% | ||
| Q2 25 | 57.5% | 12.2% | ||
| Q1 25 | 57.3% | 11.7% | ||
| Q4 24 | 50.9% | 12.1% | ||
| Q3 24 | 52.2% | 12.3% | ||
| Q2 24 | 58.2% | 12.3% | ||
| Q1 24 | 57.3% | 12.4% |
| Q4 25 | -22.6% | 10.1% | ||
| Q3 25 | -4.4% | 9.6% | ||
| Q2 25 | 2.0% | 9.8% | ||
| Q1 25 | 5.0% | 9.0% | ||
| Q4 24 | -5.0% | 9.5% | ||
| Q3 24 | 54.3% | 9.6% | ||
| Q2 24 | -2.7% | 9.7% | ||
| Q1 24 | 1.0% | 9.7% |
| Q4 25 | -24.1% | 9.9% | ||
| Q3 25 | -3.0% | 9.8% | ||
| Q2 25 | 0.9% | 9.6% | ||
| Q1 25 | 5.6% | 9.3% | ||
| Q4 24 | -0.8% | 10.4% | ||
| Q3 24 | 35.3% | 9.6% | ||
| Q2 24 | -4.2% | 10.8% | ||
| Q1 24 | 2.7% | 11.1% |
| Q4 25 | $-0.55 | $3.11 | ||
| Q3 25 | $-0.07 | $2.66 | ||
| Q2 25 | $0.02 | $2.41 | ||
| Q1 25 | $0.13 | $2.25 | ||
| Q4 24 | $-0.01 | $2.38 | ||
| Q3 24 | $0.73 | $2.13 | ||
| Q2 24 | $-0.10 | $2.22 | ||
| Q1 24 | $0.06 | $2.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $960.8M |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $2.2B |
| Total Assets | $13.4B | $3.3B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $960.8M | ||
| Q3 25 | $505.0M | $968.8M | ||
| Q2 25 | $539.0M | $934.2M | ||
| Q1 25 | $487.0M | $950.7M | ||
| Q4 24 | $468.0M | $934.6M | ||
| Q3 24 | $490.0M | $908.9M | ||
| Q2 24 | $416.0M | $858.6M | ||
| Q1 24 | $345.0M | $794.0M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $2.2B | ||
| Q3 25 | $6.7B | $2.1B | ||
| Q2 25 | $6.8B | $2.0B | ||
| Q1 25 | $6.4B | $1.9B | ||
| Q4 24 | $6.1B | $1.8B | ||
| Q3 24 | $6.5B | $1.8B | ||
| Q2 24 | $5.9B | $1.7B | ||
| Q1 24 | $6.1B | $1.7B |
| Q4 25 | $13.4B | $3.3B | ||
| Q3 25 | $13.6B | $3.0B | ||
| Q2 25 | $13.7B | $2.8B | ||
| Q1 25 | $12.9B | $2.6B | ||
| Q4 24 | $12.6B | $2.5B | ||
| Q3 24 | $13.3B | $2.4B | ||
| Q2 24 | $13.8B | $2.3B | ||
| Q1 24 | $14.0B | $2.2B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $46.3M |
| Free Cash FlowOCF − Capex | $46.0M | $-5.3M |
| FCF MarginFCF / Revenue | 4.0% | -0.5% |
| Capex IntensityCapex / Revenue | 5.4% | 4.6% |
| Cash ConversionOCF / Net Profit | — | 0.41× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $102.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $46.3M | ||
| Q3 25 | $219.0M | $102.6M | ||
| Q2 25 | $237.0M | $55.1M | ||
| Q1 25 | $-4.0M | $74.2M | ||
| Q4 24 | $177.0M | $115.9M | ||
| Q3 24 | $162.0M | $83.2M | ||
| Q2 24 | $200.0M | $83.1M | ||
| Q1 24 | $2.0M | $100.9M |
| Q4 25 | $46.0M | $-5.3M | ||
| Q3 25 | $127.0M | $57.3M | ||
| Q2 25 | $180.0M | $4.7M | ||
| Q1 25 | $-69.0M | $45.7M | ||
| Q4 24 | $130.0M | $94.0M | ||
| Q3 24 | $120.0M | $62.9M | ||
| Q2 24 | $166.0M | $70.4M | ||
| Q1 24 | $-22.0M | $87.3M |
| Q4 25 | 4.0% | -0.5% | ||
| Q3 25 | 11.2% | 5.9% | ||
| Q2 25 | 14.5% | 0.5% | ||
| Q1 25 | -5.8% | 5.2% | ||
| Q4 24 | 12.7% | 11.3% | ||
| Q3 24 | 11.7% | 7.8% | ||
| Q2 24 | 14.0% | 9.3% | ||
| Q1 24 | -1.8% | 11.9% |
| Q4 25 | 5.4% | 4.6% | ||
| Q3 25 | 8.1% | 4.6% | ||
| Q2 25 | 4.6% | 5.5% | ||
| Q1 25 | 5.4% | 3.3% | ||
| Q4 24 | 4.6% | 2.6% | ||
| Q3 24 | 4.1% | 2.5% | ||
| Q2 24 | 2.9% | 1.7% | ||
| Q1 24 | 2.0% | 1.9% |
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | 1.07× | ||
| Q2 25 | 21.55× | 0.63× | ||
| Q1 25 | -0.06× | 0.91× | ||
| Q4 24 | — | 1.34× | ||
| Q3 24 | 0.45× | 1.07× | ||
| Q2 24 | — | 1.02× | ||
| Q1 24 | 0.06× | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
FN
| Optical Communications | $832.6M | 73% |
| Non Optical Communications | $300.3M | 27% |
